Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study

被引:61
作者
Caputo, F
Addolorato, G
Lorenzini, F
Domenicali, M
Greco, G
del Re, A
Gasbarrini, G
Stefanini, GF
Bernardi, M
机构
[1] Univ Bologna, G Fontana Ctr Study & Treatment Alcohol Addict, Dept Internal Med Cardioangiol & Hepatol, I-40138 Bologna, Italy
[2] Univ Cattolica Sacro Cuore, Inst Internal Med, I-00168 Rome, Italy
[3] Serv Addict Treatment, Ravenna, Italy
[4] Osped Infermi, Dept Internal Med, Faenza, Italy
关键词
pharmacotherapy; gamma-hydroxybutyric acid; naltrexone; maintaining abstinence from alcohol;
D O I
10.1016/S0376-8716(02)00340-X
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Maintaining abstinence from alcohol is the main goal in the treatment of alcohol dependence. Naltrexone (NTX) and gamma-hydroxybutyric acid (GHB) have proved able to maintain alcohol abstinence in alcoholic subjects. The aim of our study was to evaluate the efficacy of GHB compared with NTX in maintaining abstinence from alcohol after 3 months of treatment. A total of 35 alcohol-dependent outpatients were randomly enrolled in two groups: the GHB group consisted of 18 patients treated with oral doses of GHB (50 mg/kg of body weight t.i.d) for 3 months; the NTX group consisted of 17 patients treated with oral doses of NTX (50 mg/day) for 3 months. At the end of the study, a statistically significant difference (P = 0.02) was found in the number of abstinent patients between the GHB and the NTX groups. In patients who failed to be abstinent, no relapses in heavy drinking were observed in the NTX group, while in the GHB group all patients relapsed. The results of the present study show that GHB is more effective than NTX in maintaining abstinence from alcohol in a short-term treatment period; on the other hand, NTX confirmed its ability to reduce alcohol relapses. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 43 条
[41]  
VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
[42]   Comparison of acamprosate and placebo in long-term treatment of alcohol dependence [J].
Whitworth, AB ;
Fischer, F ;
Lesch, OM ;
Nimmerrichter, A ;
Oberbauer, H ;
Platz, T ;
Potgieter, A ;
Walter, H ;
Fleischhacher, WW .
LANCET, 1996, 347 (9013) :1438-1442
[43]   Adverse events, including death, associated with the use of 1,4-butanediol. [J].
Zvosec, DL ;
Smith, SW ;
McCutcheon, JR ;
Spillane, J ;
Hall, BJ ;
Peacock, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (02) :87-94